Ekinci F.Balcik O.Y.Oktay E.Erdogan A.P.2024-07-222024-07-2220221022386Xhttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/12849Objective: To evaluate prognostic significance of the new index, designed by formulating hemoglobin, albumin, lymphocyte, and platelet (HALP) counts in patients with metastatic renal cell carcinoma (RCC). Study Design: Descriptive study. Place and Duration of Study: Department of Medical Oncology, Celal Bayar University, Manisa, Turkey and Adnan Menderes University, Aydin, Turkey, from January 2014 to April 2020. Methodology: Patients with metastatic RCC and sufficient follow-up data were included in the study as a retrospective cohort. HALP score was calculated as hemoglobin (g/L) × albumin (g/L) levels × lymphocyte count (/L)/platelet count (/L). The cut-off value was determined by examining the area under the ROC curve for the HALP value. The endpoints of this study included overall survival (OS) and progression-free survival (PFS). Results: The mean overall survival (OS) of the patients with low HALP score was 17.7 months (95% CI, 2.21 - 33.18), while the OS of the patients with high HALP score was 89.7 months (95% CI, 55.62 - 123.77) and reached statistical significance (p=0.001). The results of univariate (p = 0.009) and multivariate (p=0.012) analyses were statistically significant as well. Conclusion: The HALP score in metastatic RCC patients was closely related to the prognosis. Worse OS was found in patients with a low HALP score. © 2022 College of Physicians and Surgeons Pakistan. All rights reserved.EnglishAll Open Access; Gold Open AccessAlbuminsCarcinoma, Renal CellHemoglobinsHumansKidney NeoplasmsLymphocytesPrognosisRetrospective StudiesalbuminhemoglobinalbuminoidhemoglobinadultagedArticlecancer patientcancer prognosiscohort analysisconfidence intervalcontrolled studydescriptive researchdiagnostic test accuracy studyfemalefollow uphemoglobin albumin lymphocyte and platelet scorehumankidney metastasislymphocyte countmajor clinical studymalemultivariate analysisoverall survivalplatelet countprogression free survivalreceiver operating characteristicretrospective studyscoring systemsensitivity and specificitystatistical significanceTurkey (republic)univariate analysiskidney tumorlymphocyteprognosisrenal cell carcinomaArticle10.29271/jcpsp.2022.03.313